• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

保险延迟启动儿童幼年特发性关节炎肿瘤坏死因子抑制剂。

Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis.

机构信息

Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Netw Open. 2022 Apr 1;5(4):e228330. doi: 10.1001/jamanetworkopen.2022.8330.

DOI:10.1001/jamanetworkopen.2022.8330
PMID:35446398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9024383/
Abstract

This cohort study compares the delays in tumor necrosis factor inhibitor (TNFi) initiation because of insurance among children enrolled in public and private insurance plans.

摘要

本队列研究比较了在公共和私人保险计划中，因保险原因导致儿童开始使用肿瘤坏死因子抑制剂 (TNFi) 的延迟。

相似文献

1
Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis.保险延迟启动儿童幼年特发性关节炎肿瘤坏死因子抑制剂。
JAMA Netw Open. 2022 Apr 1;5(4):e228330. doi: 10.1001/jamanetworkopen.2022.8330.
2
Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry.保险状况与儿童类风湿关节炎患者肿瘤坏死因子抑制剂的使用：CARRA 注册研究
J Rheumatol. 2023 Aug;50(8):1047-1057. doi: 10.3899/jrheum.220871. Epub 2022 Dec 15.
3
Genetic Variants and Therapeutic Response to Anti-TNF-α Agents in Juvenile Idiopathic Arthritis: An Updated Systematic Review and Meta-analysis.青少年特发性关节炎中基因变异与抗TNF-α药物治疗反应：一项更新的系统评价与Meta分析
J Clin Rheumatol. 2022 Oct 1;28(7):374-378. doi: 10.1097/RHU.0000000000001835. Epub 2022 Jun 29.
4
Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis).治疗青少年类风湿性关节炎（青少年特发性关节炎）的新型疗法。
Expert Opin Investig Drugs. 2003 Jan;12(1):19-28. doi: 10.1517/13543784.12.1.19.
5
Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin.雷帕霉素成功治疗难治性系统性幼年特发性关节炎。
Rheumatology (Oxford). 2021 Jul 1;60(7):e250-e251. doi: 10.1093/rheumatology/keab114.
6
Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.新冠信使核糖核酸疫苗在接受肿瘤坏死因子抑制剂治疗的青少年特发性关节炎青少年中的安全性和耐受性。
Arthritis Rheumatol. 2022 Feb;74(2):365-366. doi: 10.1002/art.41977. Epub 2022 Jan 4.
7
Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy.抗肿瘤坏死因子治疗使侵蚀性银屑病性幼年特发性关节炎迅速缓解
J Clin Rheumatol. 2021 Dec 1;27(8S):S688-S689. doi: 10.1097/RHU.0000000000001602.
8
The Effect of Tumor Necrosis Factor α Blockers on Growth Velocity in Juvenile Idiopathic Arthritis.肿瘤坏死因子α阻滞剂对幼年特发性关节炎生长速度的影响。
J Clin Rheumatol. 2015 Oct;21(7):376-8. doi: 10.1097/RHU.0000000000000308.
9
Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.抗阿达木单抗抗体动力学：幼年特发性关节炎（JIA）转换的早期指导。
Clin Rheumatol. 2020 Feb;39(2):515-521. doi: 10.1007/s10067-019-04798-6. Epub 2019 Nov 9.
10
Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.肿瘤坏死因子-α抑制剂在儿童及青少年特发性关节炎或类风湿关节炎患者中的应用
Pharmacotherapy. 2016 Dec;36(12):1201-1209. doi: 10.1002/phar.1856. Epub 2016 Dec 4.

引用本文的文献

1
Sociodemographic and Visual Outcomes of Juvenile Idiopathic Arthritis Uveitis: IRIS Registry Study.青少年特发性关节炎葡萄膜炎的社会人口统计学和视觉预后：IRIS注册研究
Clin Ophthalmol. 2024 May 8;18:1257-1266. doi: 10.2147/OPTH.S456252. eCollection 2024.
2
Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry.保险状况与儿童类风湿关节炎患者肿瘤坏死因子抑制剂的使用：CARRA 注册研究
J Rheumatol. 2023 Aug;50(8):1047-1057. doi: 10.3899/jrheum.220871. Epub 2022 Dec 15.

本文引用的文献

1
Underinsurance Among Children in the United States.美国儿童的保险不足问题。
Pediatrics. 2022 Jan 1;149(1). doi: 10.1542/peds.2021-050353.
2
Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study.与输注药物的事先授权相关的治疗延迟：一项队列研究。
Arthritis Care Res (Hoboken). 2020 Nov;72(11):1543-1549. doi: 10.1002/acr.24062.
3
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis.计划层面的准入限制对类风湿性关节炎或银屑病关节炎患者生物制剂疗效的影响
Pharmacoecon Open. 2020 Mar;4(1):105-117. doi: 10.1007/s41669-019-0152-1.
4
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.2019 年美国风湿病学会/关节炎基金会治疗幼年特发性关节炎指南：非系统性多关节炎、骶髂关节炎和附着点炎的治疗方法。
Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-734. doi: 10.1002/acr.23870. Epub 2019 Apr 25.
5
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.青少年特发性关节炎治疗中药物使用的近期趋势及肿瘤坏死因子抑制剂的影响。
J Rheumatol. 2014 Oct;41(10):2078-84. doi: 10.3899/jrheum.140012. Epub 2014 Aug 1.
6
Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis.在少数族裔和处境不利的类风湿关节炎患者中启动改善病情抗风湿药物治疗
J Rheumatol. 2007 Dec;34(12):2400-7. Epub 2007 Nov 1.